ACT LISINOPRIL TABLET

País: Canadá

Língua: inglês

Origem: Health Canada

Ingredientes ativos:

LISINOPRIL (LISINOPRIL DIHYDRATE)

Disponível em:

ACTAVIS PHARMA COMPANY

Código ATC:

C09AA03

DCI (Denominação Comum Internacional):

LISINOPRIL

Dosagem:

10MG

Forma farmacêutica:

TABLET

Composição:

LISINOPRIL (LISINOPRIL DIHYDRATE) 10MG

Via de administração:

ORAL

Unidades em pacote:

100/500

Tipo de prescrição:

Prescription

Área terapêutica:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Resumo do produto:

Active ingredient group (AIG) number: 0121550001; AHFS:

Status de autorização:

CANCELLED POST MARKET

Data de autorização:

2018-06-12

Características técnicas

_______________________________________________________________________________________________
_ACT LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 43 _
_ _
_ _
PRODUCT MONOGRAPH
PR
ACT_ _LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Actavis Pharma Company
6733 Mississauga Road, Suite 400
Mississauga, Ontario
Canada, L5N 6J5
Control Number: 208042
Date of Revision:
September 20, 2017
_______________________________________________________________________________________________
_ACT LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 43 _
_ _
_ _
_PR _
ACT_ _LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
Angiotensin Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
Lisinopril is an angiotensin converting enzyme (ACE) inhibitor which
is used in the treatment of
hypertension, congestive heart failure and following myocardial
infarction in hemodynamically
stable patients.
ACE is a peptidyl dipeptidase which catalyzes the conversion of
angiotensin I to the pressor
substance, angiotensin II. Inhibition of ACE results in decreased
plasma angiotensin II, which
leads to increased plasma renin activity (due to removal of negative
feedback of renin release)
and decreased aldosterone secretion. Although the latter decrease is
small, it results in a small
increase in serum potassium. In patients treated with lisinopril and a
thiazide diuretic there was
essentially no change in serum potassium (see PRECAUTIONS).
ACE is identical to kininase II. Thus, lisinopril may also block the
degradation of bradykinin, a
potent vasodilator peptide. However, the role that this plays in the
therapeutic effects of
lisinopril is unknown.
While the mechanism through which lisinopril lowers blood pressure is
believed to be primarily
the suppression of the renin-angiotensin-aldosterone system (RAAS),
lisinopril also lowers blood
pressure in patients with low-renin hypertension.
PHARMACODYNA